Non-invasive continuous positive airway pressure for preterm neonatal respiratory distress — recruitment, titration, interface, and failure escalation
Respiratory distress syndrome (RDS), driven by surfactant deficiency in the immature preterm lung, was historically managed by early intubation and mechanical ventilation. Over the past two decades, the neonatology field has shifted decisively toward non-invasive nasal continuous positive airway pressure (CPAP) as the preferred initial respiratory support strategy — delivering continuous distending pressure through soft nasal prongs or a mask, with no endotracheal tube, sedation, or ventilator-induced lung injury required.
Endotracheal intubation and mechanical ventilation, while life-saving, carry well-documented risks in the preterm lung: ventilator-induced lung injury (volutrauma, barotrauma), increased risk of bronchopulmonary dysplasia (BPD), airway trauma, and the need for sedation that can itself depress respiratory drive. Landmark multicenter trials (COIN, SUPPORT, VON) in the 2000s demonstrated that starting eligible preterm infants on CPAP in the delivery room, reserving intubation for those who fail non-invasive support, reduces rates of BPD or death without increasing other serious complications.
This "CPAP first" philosophy is now embedded in international neonatal resuscitation and RDS management guidelines. It does not eliminate the need for intubation in the sickest infants — but it meaningfully shrinks the population exposed to invasive ventilation and its downstream morbidity.
Nasal CPAP systems apply a continuous, set distending pressure to the airway throughout the respiratory cycle — during both inspiration and expiration — via short binasal prongs, a single nasal prong, or a nasal mask connected to a pressure-generating circuit (bubble CPAP, ventilator-derived CPAP, or a variable-flow device). Because there is no tube inside the trachea, the infant retains their natural upper-airway reflexes, can cry, feed transitionally, and requires no paralytic or deep sedation.
Selecting CPAP as the initial strategy is most appropriate for infants with mild-to-moderate work of breathing, adequate spontaneous respiratory drive, and no absolute indication for immediate intubation (e.g., need for surfactant in a peri-viable infant per unit protocol, severe apnea, or cardiovascular instability).
The clinical logic is straightforward: give the preterm lung continuous distending pressure to do the mechanical work that surfactant deficiency prevents it from doing alone — without the added risks that come with placing a tube in the trachea.
The therapeutic core of CPAP is mechanical: a constant positive pressure applied to the airway opposes the tendency of surfactant-deficient alveoli to collapse at end-expiration. By holding small airways and alveoli open throughout the breathing cycle, CPAP increases functional residual capacity (FRC), improves ventilation-perfusion matching, and reduces the work of breathing needed to reinflate collapsed lung units with every breath.
Pulmonary surfactant, produced by type II pneumocytes, reduces alveolar surface tension and prevents the smallest alveoli from collapsing at low lung volumes (per LaPlace's law, collapsing pressure rises as alveolar radius shrinks). Preterm infants, particularly those born before 34 weeks gestation, often have insufficient surfactant production, causing progressive atelectasis, reduced lung compliance, and increasing respiratory effort — the hallmark pathophysiology of RDS.
Without intervention, each expiration allows previously open alveoli to collapse, forcing the infant to generate much greater inspiratory pressure on the next breath to reopen them — a cycle that rapidly exhausts a preterm infant's limited respiratory reserve.
By maintaining a constant positive pressure at the airway opening throughout expiration, CPAP acts as a pneumatic splint: it prevents alveoli and small airways from collapsing below their critical opening pressure. This is mechanistically analogous to positive end-expiratory pressure (PEEP) on a mechanical ventilator, but delivered without an endotracheal tube.
Recruited, stably open alveoli translate into a larger functional residual capacity — the volume of air remaining in the lungs at the end of a normal expiration. A higher FRC improves gas exchange surface area, reduces intrapulmonary shunting, and substantially lowers the metabolic and mechanical work of breathing, because the infant no longer needs to generate a large opening pressure with each inspiration.
CPAP does not deliver breaths — it does not actively ventilate. Its entire therapeutic effect comes from preventing collapse and reducing the work required for the infant's own spontaneous breaths, which is why adequate spontaneous respiratory drive is a prerequisite for CPAP to succeed.
CPAP is not a fixed, one-size-fits-all prescription. The applied pressure is titrated for each infant based on clinical work of breathing, supplemental oxygen requirement, and radiographic lung expansion — seeking the pressure that recruits collapsed alveoli without overdistending already-open ones, which can itself impair gas exchange and risk air-leak syndromes.
Clinicians titrate CPAP pressure upward when an infant shows persistent signs of increased work of breathing — tachypnea, subcostal and intercostal retractions, nasal flaring, grunting — combined with a rising supplemental oxygen requirement to maintain target saturations. These findings suggest under-recruited lung: more alveoli remain collapsed than the current pressure can hold open.
Conversely, pressure is reduced (or held rather than increased) when the chest X-ray shows well-expanded, well-aerated lungs (roughly 8-9 posterior rib spaces of expansion), oxygen requirement is low and stable, and work of breathing is minimal — signs that further pressure would risk overdistension rather than add benefit.
Too little pressure under-recruits the lung, leaving atelectasis, hypoxemia, and increased work of breathing unaddressed. Too much pressure overdistends already-open alveoli, which can compress adjacent pulmonary capillaries, increase dead space, raise intrathoracic pressure enough to impede venous return and cardiac output, and increase the risk of air-leak syndromes such as pneumothorax or pulmonary interstitial emphysema.
The titration goal is the "just right" pressure for that infant's lung compliance at that point in time — a moving target that requires reassessment as compliance improves with surfactant production, treatment, and postnatal maturation.
Pressure titration on CPAP is a continuous feedback loop, not a one-time decision: work of breathing, oxygen need, and chest imaging are reassessed repeatedly, and the pressure is adjusted in small increments to track the infant's evolving lung mechanics.
CPAP can only deliver the pressure it is set to deliver if that pressure actually reaches the airway. Proper sizing and secure application of the nasal prong or mask interface, and minimization of air leak around the nares, mouth, and circuit connections, is a deceptively simple but clinically critical determinant of whether CPAP succeeds or silently under-treats the infant.
CPAP devices are typically open, high-flow systems: a continuous gas flow is delivered against a resistance (underwater seal, ventilator valve, or variable-flow generator) to create the set pressure. If a significant leak develops — from prongs that are too small for the nares, a poorly fitted mask, an open mouth, or a loose circuit connection — gas escapes before building the intended pressure, and the alveolar recruitment effect described earlier is proportionally lost, even though the device display may still show the "set" pressure.
An infant on CPAP with a large leak can appear to be receiving therapy while actually experiencing progressive under-recruitment and worsening work of breathing — leak should always be considered when a CPAP patient is not responding as expected to a pressure increase.
Correct prong or mask sizing aims for a snug seal that fills the nares without occluding them or blanching the surrounding skin. Many units alternate periodically between nasal prongs and a nasal mask to redistribute pressure points and reduce the risk of nasal septal injury or pressure necrosis from prolonged, continuous contact — a well-recognized complication of long CPAP courses.
Bedside nursing and respiratory therapy monitoring includes visually confirming interface position, checking for audible leak, keeping the mouth closed (chin strap or positioning) when using nasal-only interfaces, and reassessing fit as the infant grows or the face becomes edematous — all practical, unglamorous tasks that are nonetheless essential to CPAP actually delivering the pressure it is prescribed to deliver.
A CPAP device can be set correctly and still fail the infant if the interface leaks — leak management is not a peripheral nursing detail, it is a core part of whether the physiologic mechanism described in Stage 2 actually occurs.
CPAP is a powerful first-line tool, but it is not sufficient for every infant, and recognizing failure promptly is as important as starting CPAP promptly. Persistent or worsening work of breathing, recurrent apnea, or a rising oxygen requirement despite an optimized trial of CPAP — appropriate pressure, well-fitted interface, adequately treated leak — are the signals that prompt escalation to surfactant administration and/or intubation with mechanical ventilation.
CPAP failure is generally defined clinically as persistent or escalating respiratory distress despite an adequately optimized trial of non-invasive support — meaning the pressure has been titrated appropriately, the interface fit and leak have been checked, and the infant has still not stabilized. Common failure criteria used across units include a sustained FiO2 requirement above a defined threshold (often in the 40-50% range) to maintain target saturations, recurrent or severe apnea unresponsive to stimulation and caffeine therapy, significant respiratory acidosis on blood gas, or persistent severe work of breathing.
Because these thresholds are unit- and protocol-specific, the underlying clinical principle matters more than any single number: CPAP failure is a moving assessment based on trend, not a single data point, and clinicians must distinguish transient dips from a true failure trajectory.
When CPAP failure is recognized, two escalation pathways are commonly used, sometimes in combination. The first is exogenous surfactant administration, which can be delivered via brief intubation followed by rapid extubation back to CPAP (the INSURE technique: Intubate-Surfactant-Extubate), or via less invasive surfactant administration (LISA/MIST) techniques that instill surfactant through a thin catheter while the infant remains on CPAP throughout. Surfactant replacement directly addresses the underlying deficiency driving alveolar collapse and can allow many infants to remain on, or quickly return to, non-invasive support.
The second pathway is full intubation and conventional (or high-frequency) mechanical ventilation, reserved for infants who fail surfactant-supported CPAP or who have more severe instability requiring the greater control over ventilation and oxygenation that invasive support provides.
The decision to escalate is a safety-first judgment: continuing to "wait and see" on CPAP once true failure criteria are met risks progressive hypoxemia, fatigue, and cardiorespiratory decompensation — timely escalation to surfactant and/or ventilation is part of using CPAP responsibly, not a failure of the non-invasive strategy itself.